SCHEMBL22675913

SCHEMBL22675913

CC#CC(=O)Nc1ccc(-c2c(-c3ccc(Oc4cccc(C)n4)c(OC)c3)c3c(N)ncnc3n2C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 2/20 0.53
▸ FGFR2 P21802 2/20 0.53
▸ FGFR4 P22455 2/20 0.53
▸ FGFR3 P22607 2/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ BTK Q06187 6/20 0.40
▸ LCK P06239 3/20 0.39
▸ AURKA O14965 1/20 0.39
▸ IKBKE Q14164 1/20 0.39
▸ AURKB Q96GD4 1/20 0.39
▸ KDR P35968 6/20 0.38
▸ TEK Q02763 4/20 0.38
▸ KIT P10721 2/20 0.38
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ CDK5 Q00535 1/20 0.36
▸ CDK5R1 Q15078 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30303979 1.00 FGFR1 (0.53) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL30304029 0.89 FGFR1 (0.53) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL22675934 0.89 FGFR1 (0.53) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL22675910 0.88 FGFR1 (0.55) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL30303545 0.88 FGFR1 (0.55) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL22675914 0.88 FGFR1 (0.68) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL30303682 0.88 FGFR1 (0.68) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL22676605 0.88 FGFR1 (0.52) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL30303331 0.88 FGFR1 (0.52) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL22675916 0.87 CYP3A4 (0.45) FGFR1FGFR2FGFR4FGFR3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4306529-A2 FGFR INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2024-01-17 — — EP disclosed
US-11780845-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-11780845-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-20230104574-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF D.E. SHAW RESEARCH, LLC 2023-04-06 — — US disclosed
WO-2020231990-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2020-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR2 2/4885FGFR4 4/4885
US-20230104574-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR2 2/4885FGFR4 4/4885
US-11780845-B2 FGFR inhibitors and methods of use thereof FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR2 2/4885FGFR4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback